Cargando…
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552408/ https://www.ncbi.nlm.nih.gov/pubmed/26322224 http://dx.doi.org/10.1186/s13569-015-0035-x |
| _version_ | 1782387722346823680 |
|---|---|
| author | Wagner, Lars M. |
| author_facet | Wagner, Lars M. |
| author_sort | Wagner, Lars M. |
| collection | PubMed |
| description | Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents. |
| format | Online Article Text |
| id | pubmed-4552408 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45524082015-08-29 Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Wagner, Lars M. Clin Sarcoma Res Review Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents. BioMed Central 2015-08-28 /pmc/articles/PMC4552408/ /pubmed/26322224 http://dx.doi.org/10.1186/s13569-015-0035-x Text en © Wagner. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Review Wagner, Lars M. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title_full | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title_fullStr | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title_full_unstemmed | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title_short | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| title_sort | fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552408/ https://www.ncbi.nlm.nih.gov/pubmed/26322224 http://dx.doi.org/10.1186/s13569-015-0035-x |
| work_keys_str_mv | AT wagnerlarsm fifteenyearsofirinotecantherapyforpediatricsarcomawheretonext |